Resources from the same session
5247 - 1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109).
Presenter: Michael Geissler
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
5012 - Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or single-agent Pan: translational analyses of the VALENTINO study
Presenter: Federica Morano
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
2307 - Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
Presenter: Hiroya Taniguchi
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Poster Discussion session - Gastrointestinal tumours, colorectal 1 - Invited Discussant 453PD, LBA22 and 454PD
Presenter: Fortunato Ciardiello
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Slides
Webcast
2100 - NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
Presenter: Stine Winther
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
5869 - Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Metastatic Colorectal Cancer (mCRC)
Presenter: John Hays
Session: Poster Discussion session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract